435 related articles for article (PubMed ID: 33161790)
1. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report.
Lu J; Tang S; Yu N; Yi X; Li Y
J Int Med Res; 2020 Nov; 48(11):300060520969494. PubMed ID: 33161790
[TBL] [Abstract][Full Text] [Related]
2. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
[TBL] [Abstract][Full Text] [Related]
3. Recalcitrant psoriatic uveitis and anti-tumor necrosis factor-α monoclonal antibodies: experience from a psoriasis referral center.
Fotiadou C; Lazaridou E; Kemanetzi C; Kyrmanidou E; Ioannides D
Int J Dermatol; 2015 Sep; 54(9):1105-8. PubMed ID: 25557117
[TBL] [Abstract][Full Text] [Related]
4. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
5. Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
[TBL] [Abstract][Full Text] [Related]
6. Osteomyelitis occurring during infliximab treatment of severe psoriasis.
Sri JC; Tsai CL; Deng A; Gaspari AA
J Drugs Dermatol; 2007 Feb; 6(2):207-10. PubMed ID: 17373180
[TBL] [Abstract][Full Text] [Related]
7. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
Hamilton TK
J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab: A Review in Psoriatic Arthritis.
Shirley M; Scott LJ
Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
[TBL] [Abstract][Full Text] [Related]
9. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab: first global approval.
Sanford M; McKeage K
Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
[TBL] [Abstract][Full Text] [Related]
11. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
12. Psoriasis vulgaris patient with psoriatic arthritis managed with interleukin-17A inhibitor: Balancing benefits and adverse effects.
Utama WS; Lestari W; Hajar S; Sylvawani M; Ismida FD; Akele RY
Narra J; 2024 Apr; 4(1):e207. PubMed ID: 38798877
[TBL] [Abstract][Full Text] [Related]
13. Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature.
Hsieh CY; Tsai TF
Lupus; 2022 Jun; 31(7):891-894. PubMed ID: 35438595
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab therapy of psoriasis and psoriatic arthritis in a patient with cirrhosis of the liver.
Piel S; Dissemond J
J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S117-8. PubMed ID: 19119119
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.
Schweikert B; Malmberg C; Núñez M; Dilla T; Sapin C; Hartz S
BMJ Open; 2020 Aug; 10(8):e032552. PubMed ID: 32792421
[TBL] [Abstract][Full Text] [Related]
16. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
17. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
[TBL] [Abstract][Full Text] [Related]
18. Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Hoit Marchlewicz E; Shrady G; Zhao Y; Mendelsohn AM
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755976
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
[TBL] [Abstract][Full Text] [Related]
20. [Biological treatment of psoriasis and psoriatic arthritis].
Kragballe K; Deleuran B
Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
